26 patents
Utility
Treatment of Fragile X Syndrome with Cannabidiol
23 Feb 23
The present technology relates to a method of treating one or more behavioral symptoms of autism spectrum disorder (ASD) in a subject by administering an effective amount of cannabidiol (CBD).
Joseph Palumbo, Stephen V. O'Quinn, Terri Sebree, Marcel Bonn-Miller, Donna Gutterman
Filed: 20 Oct 22
Utility
Treatment of 22Q11.2 Deletion Syndrome with Cannabidiol
26 Jan 23
The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of 22q11.2 deletion syndrome are treated in the subject
Terri Sebree, Donna Gutterman
Filed: 30 Sep 22
Utility
Treatment of Fragile X Syndrome with Cannabidiol
5 Jan 23
The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
Filed: 24 Aug 22
Utility
Treatment of 22Q11.2 Deletion Syndrome with Cannabidiol
5 Jan 23
The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral and/or psychiatric symptoms of 22q11.2 deletion syndrome are treated in the subject
Terri Sebree, Donna Gutterman
Filed: 9 Sep 22
Utility
Treatment of 22Q11.2 Deletion Syndrome with Cannabidiol
5 Jan 23
The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral and/or psychiatric symptoms of 22q11.2 deletion syndrome are treated in the subject
Terri Sebree, Donna Gutterman
Filed: 9 Sep 22
Utility
Treatment of 22Q11.2 deletion syndrome with cannabidiol
4 Oct 22
The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of 22q11.2 deletion syndrome are treated in the subject.
Terri Sebree, Donna Gutterman
Filed: 12 Dec 19
Utility
Treatment of Fragile X Syndrome with cannabidiol
4 Oct 22
The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
Filed: 6 Aug 20
Utility
Treatment of Behavioral Impairment In Developmental and Epileptic Encephalopathy
14 Jul 22
The present technology relates to methods of treating behavioral problems and seizures in a subject having developmental and epileptic encephalopathy (DEE) by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein behavioral problems are treated in the subject.
Terri Sebree, Donna Gutterman, John Messenheimer
Filed: 17 Mar 22
Utility
Prodrugs of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same
23 Jun 22
Described herein are Δ9-THC prodrugs, methods of making Δ9-THC prodrugs, formulations comprising Δ9-THC prodrugs and methods of using Δ9-THC.
Audra Lynn Stinchcomb, Miroslaw Jerzy Golinski, Dana Carmel Hammell, Jeffrey Lynn Howard
Filed: 24 Nov 21
Utility
Treatment of Autism with Cannabidiol
31 Mar 22
The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.
Terri Sebree, Marcel Bonn-Miller, Donna Gutterman
Filed: 2 Sep 21
Utility
Treatment of Fragile X Syndrome with Cannabidiol
30 Dec 21
The present technology relates to a method of treating one or more symptoms of Full Methylation (Fmet) Fragile X Syndrome in a subject that includes administering an effective amount of cannabidiol to the subject such that one or more symptoms of Fragile X Syndrome are treated.
James Griesser, Thomas W. Dobbins, Terri Sebree
Filed: 28 Jun 21
Utility
Treatment of Fragile X Syndrome and Autism Spectrum Disorder with Cannabidiol
2 Dec 21
The present technology relates to a method of treating one or more behavioral symptoms of autism spectrum disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.
Terri Sebree, Donna Gutterman, Carol O'Neill, Joseph Palumbo
Filed: 25 May 21
Utility
Treatment of SYNGAP1 Encephalopathy
18 Mar 21
The present technology relates to methods of treating SYNGAP1 encephalopathy by transdermally administering an effective amount of cannabidiol (CBD) to the subject, wherein a SYNGAP1 symptom is treated in the subject.
Terri Sebree, John Messenheimer, Donna Gutterman
Filed: 16 Sep 20
Utility
Prodrugs of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same
18 Feb 21
Described herein are Δ9-THC prodrugs, methods of making Δ9-THC prodrugs, formulations comprising Δ9-THC prodrugs and methods of using Δ9-THC.
Audra Lynn Stinchcomb, Miroslaw Jerzy Golinski, Dana Carmel Hammell, Jeffrey Lynn Howard
Filed: 28 Aug 20
Utility
Synthetic Transdermal Cannabidiol for the Treatment of Focal Epilepsy In Adults
4 Feb 21
The present technology relates to a method of reducing seizure frequency in a subject having epilepsy by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein the seizure frequency is reduced.
Donna Gutterman, Terri Sebree, Ted Smith, John Messenheimer
Filed: 18 Aug 20
Utility
Treatment of Fragile X Sydrome with Cannabidiol
18 Nov 20
The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
Filed: 5 Aug 20
Utility
Treatment of fragile x syndrome with cannabidiol
31 Aug 20
The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
Filed: 6 Oct 19
Utility
Prodrugs of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same
5 Aug 20
Described herein are Δ9-THC prodrugs, methods of making Δ9-THC prodrugs, formulations comprising Δ9-THC prodrugs and methods of using Δ9-THC.
Audra Lynn Stinchcomb, Miroslaw Jerzy Golinski, Dana Carmel Hammell, Jeffrey Lynn Howard
Filed: 2 Feb 20
Utility
Treatment of Autism with Cannabidiol
8 Jul 20
The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.
Terri Sebree, Marcel Bonn-Miller, Donna Gutterman
Filed: 7 Jan 20
Utility
Treatment of 22Q11.2 Deletion Syndrome with Cannabidiol
17 Jun 20
The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of 22q11.2 deletion syndrome are treated in the subject
Terri Sebree, Donna Gutterman
Filed: 11 Dec 19